Regeneron Pharmaceuticals Inc. buy BiotechBee
Start price
01.11.22
/
70%
€758.30
Target price
01.11.23
€900.00
Performance (%)
-9.34%
End price
05.05.23
€687.50
Summary
This prediction ended on 05.05.23 with a price of €687.50. With a performance of -9.34%, the BUY prediction by BiotechBee finished with a loss. BiotechBee has 70% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -1.120% | -1.120% | 15.386% |
| iShares Core DAX® | 1.051% | -1.833% | 12.822% |
| iShares Nasdaq 100 | -0.547% | -3.738% | 40.625% |
| iShares Nikkei 225® | -1.778% | -8.115% | 16.092% |
| iShares S&P 500 | 0.002% | -2.226% | 28.387% |
According to BiotechBee what are the pros and cons of Regeneron Pharmaceuticals Inc. for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Cons
Comments by BiotechBee for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Buy mit Kursziel 900,0